Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 3/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192266 | 1.00 | CTSK (0.52) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL375819 | 0.87 | CTSK (0.51) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL375818 | 0.87 | CTSK (0.51) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL16228708 | 0.86 | CTSS (0.57) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL28283598 | 0.86 | CTSS (0.57) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL1863337 | 0.86 | CTSS (0.57) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL3609923 | 0.86 | CTSS (0.57) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL3782441 | 0.84 | CTSS (0.51) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL29780434 | 0.84 | CTSK (0.55) | CTSKCTSSCACNA1BAAK1HDAC4 | |
| SCHEMBL1430069 | 0.82 | CTSS (0.62) | CTSKCTSSAAK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | CTSK 2154/4885CTSS 901/4885CACNA1B 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.